Key result
Elevated IgG3, CCL5, and reduced CXCR3 T cells distinguish acute rheumatic fever with AUC 0.9.
Why the study?
The pathogenesis of acute rheumatic fever is poorly understood, limiting the development of immune-modulating therapies to treat disease and prevent progressive heart damage.
Cohort
Yes
Effect estimate: AUC 0.9 (95% CI 0.84-0.95)
Acute rheumatic fever is characterized by a distinct immunophenotype involving elevated CCL5 and IgG3, and reduced circulating CXCR3-expressing T cells that infiltrate rheumatic heart valves, highlighting potential targets for immune-modulating therapies.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for immune-modulating therapies in ARF; prospective trials needed before clinical adoption.
Middleton et al. (2026) conducted a cohort in Acute rheumatic fever. Acute rheumatic fever is characterized by elevated IgG3 and CCL5 levels alongside a reduction in circulating CXCR3-expressing T cells, distinguishing it from other conditions with an AUC of 0.9.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: